We present here results from studies of the physiological mechanisms of action of two neuropeptides widely used in clinical practice as nootropes and anxiolytics: Noopept, a peptide analog of piracetam and, Selank, a synthetic analog of the peptide tuftsin. Patch-clamp studies on hippocampal slices addressed the modulation of spontaneous inhibitory ion currents in pyramidal neurons on exposure to study neuropeptides. The main effect of both substances consisted of an increase in the frequency of spontaneous inhibitory postsynaptic currents (IPSC) in pyramidal cells of the radial layer of field CA1, evidently due to an increase in the discharge frequency of inhibitory interneurons terminating on these cells (demonstrated only for Noopept). The consequence of the increase in IPSC frequency in pyramidal neurons is strengthening of the inhibitory control of limbic structures by the hippocampus, which in turn appears to underlie the anxiolytic effects of both agents. The mechanisms of their nootropic actions will be addressed in future studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
F. Yu. Belozertsev, I. I. Kozlovskii, T. P. Semenova, and M. M. Kozlovskaya, “Effects of the neuropeptide Selank on acquisition of an adaptive spatial visual orientation skill in rats with impaired mnestic function,” Zh. Psikhofarm. Biol. Narkol., 9, 2591–2597 (2009).
T. A. Gudasheva, R. U. Ostrovskaya, F. V. Maksimova, et al., “Possible structural-functional relationships between piracetam and vasopressin,” Khim.-Farm. Zh., 3, 271–275 (1988).
T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, et al., “Peptide analogs of piracetam as ligands of presumptive nootropic receptors,” Khim.-Farm. Zh., 11, 1322–1328 (1985).
A. A. Zozulya, G. G. Neznamov, T. S. Syunyakov, et al., “Efficacy and mechanisms of action of the new peptide anxiolytic Selank in the treatment of generalized anxiety disorder and neurasthenia,” Zh. Nevrol. Psikhiat. im. Korsakova, 13, 201–210 (2008).
A. N. Chepkova, N. A. Kiapai, N. V. Doreuli, et al., “Effects of the amide pyroglutamylasparagine on the plastic properties of synaptic transmission in the hippocampus,” Byull. Eksperim. Biol. Med., 7, 68–71 (2003).
L. J. Bertoglio, S. R. Joka, and F. S. Guimaraes, “Further evidence that anxiety and memory are regionally dissociated within the hippocampus,” Behav. Brain Res., 175, 183–188 (2006).
A. N. Chepkova, P. French, D. De Wied, et al., “Long-lasting enhancement of synaptic excitability of CA1/subiculum neurons of the rat ventral hippocampus by vasopressin and vasopressin(4–8),” Brain Res., 701, No. 1–2, 255–266 (1995).
D. De Wied, “Neuropeptides in learning and memory processes,” Behav. Brain Res., 83, No. 1–2, 83–90 (1997).
P. Y. Deng, J. E. Porter, H. S. Shin, and S. Lei, “Thyrotropin-releasing hormone increases GABA release in rat hippocampus,” J. Physiol., 577, 497–511 (2006).
C. Giurgea, “Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology,” Actual Pharmacol. (Paris), 25, 115–116 (1972).
T. A. Gudasheva, S. S. Boyko, R. U. Ostrovskaya, et al., “The major metabolite of dipeptide piracetam analogue GVD-111 in right brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine,” Eur. Drug. Metab. Pharmacokinet., 22, 245–252 (1997).
T. A. Gudasheva, M. A. Konstantinopol’skii, R. U. Ostrovskaya, and S. B. Seredenin, “Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test,” Bull. Exp. Biol. Med., 131, 464–466 (2001).
J. Hughes (ed.), Centrally Acting Peptides, University Part Press (1978).
R. Kondratenko, V. I. Derevyagin, and V. G. Skrebitsky, “Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells,” Neurosci. Lett., 476, 70–73 (2010).
M. B. Kozhemiakin, A. Draguhn, and V. G. Skrebitsky, “Layer-specific potentiation of evoked IPSCs in rat hippocampal CA1 pyramidal cells by lanthanum,” Brain Res. Bull., 64, 97–101 (2004).
G. Lynch and C. M. Gall, “Ampakines and the threefold path to cognitive enhancement,” Trends Neurosci., 29, 554–672 (2006).
K. K. Miller, A. Hoffer, K. R. Svoboda, and C. R. Lupica, “Cholecystokinin increases GABA release by inhibiting a resting K+ conductance in hippocampal interneurons,” J. Neurosci., 17, 4994–5003 (1997).
H. Mohler and J. G. Richards, “Benzodiazepine receptors in the central nervous system,” in: The Benzodiazepines: From Molecular Biology to Clinical Practice, E. Costa (ed.), Raven Press, New York (1983).
R. U. Ostrovksya, M. A. Gruden, N. A. Bobkova, et al., “The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model,” J. Psychopharmacol., 21, 611–619 (2007).
B. Winblad, “Piracetam: a review of pharmacological properties and clinical uses,” CNS Drug Review, 11, 169–182 (2005).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 97, No. 11, pp. 1169–1178, November, 2011.
Rights and permissions
About this article
Cite this article
Skrebitskii, V.G., Kondratenko, R.V., Povarov, I.S. et al. Peptidergic Modulation of Synaptic Activity in the Hippocampus. Neurosci Behav Physi 43, 650–655 (2013). https://doi.org/10.1007/s11055-013-9786-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-013-9786-0